COMMUNIQUÉS West-GlobeNewswire

Solon Eiendom ASA : Sales in Q2 2018

02/07/2018 - 08:50

Oslo, July 2, 2018 - Solon Eiendom sold 107 homes with a total sales value of NOK 733 million during the second quarter of 2018 compared to 68 homes with a total sales value of NOK 685 million in the second quarter of [...]

Dr. Deborah Dunsire named new President and CEO of Lundbeck

02/07/2018 - 08:41

Valby, Denmark, 2 July 2018 - H. Lundbeck A/S (Lundbeck) today announced that the Board of Directors of the company has appointed Dr. Deborah Dunsire as new president and CEO of Lundbeck. Dr. Dunsire will take up her [...]

Solon Eiendom ASA : Primary insider notification

02/07/2018 - 08:31

(Oslo, Norway, June 29, 2018) UFI AS has today bought 2.490 shares in Solon Eiendom ASA at a price of NOK 30.10 per share. Solon Eiendom ASA Board Member Øystein A. Landvik owns 33,34 % of the shares in UFI AS. [...]

NOTICE OF BIOHIT OYJ’S EXTRAORDINARY GENERAL MEETING

02/07/2018 - 08:30

Biohit Oyj Stock Exchange Release July 2, 2018 at 9:30 am local time (EEST) Biohit Oyj shareholders are invited to attend the Extraordinary General Meeting of Biohit Oyj to be held on Thursday, August 16, 2018 starting [...]

Shire plc: Director/PDMR Shareholding

02/07/2018 - 08:01

Director/PDMR Shareholding July 2, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) Notification of transactions by persons discharging managerial responsibilities 1. Details of the person discharging managerial [...]

Shire plc : Form 8 (DD) - Albert Stroucken

02/07/2018 - 08:01

FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code") [...]

Shire plc : Form 8 (DD) - Gail Fosler

02/07/2018 - 08:01

FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code") [...]

Shire plc : Form 8 (DD) - Steven Gillis

02/07/2018 - 08:01

FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code") [...]

Shire plc : Form 8 (DD) - David Ginsburg

02/07/2018 - 08:01

FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code") [...]

Shire plc : Form 8 (DD) - Sara Mathew

02/07/2018 - 08:01

FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code") [...]

Shire plc : Form 8 (DD) - Ian Clark

02/07/2018 - 08:01

FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code") [...]

Shire plc : Form 8 (DD) - Susan Kilsby

02/07/2018 - 08:01

FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code") [...]

Shire plc : Form 8 (DD) - Olivier Bohuon

02/07/2018 - 08:01

FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the "Code") [...]

Shire plc : CHMP RECOMMENDS EU MARKETING AUTHORIZATION FOR VEYVONDI(R) FOR ADULTS WITH VON WILLEBRAND DISEASE

02/07/2018 - 08:01

CHMP RECOMMENDS EU MARKETING AUTHORIZATION FOR VEYVONDI ® [VONICOG ALFA, RECOMBINANT VON WILLEBRAND FACTOR] FOR ADULTS WITH VON WILLEBRAND DISEASE If approved, VEYVONDI ® [ vonicog alfa, recombinant von Willebrand [...]

OSE Immunotherapeutics Receives IDMC Approval to Continue “Atalante 1” Phase 3 NSCLC Clinical Trial of Tedopi®

02/07/2018 - 08:00

Trial in Non-Small Cell Lung Cancer (NSCLC) Patients After Immune Checkpoint Inhibitor Failure Checkpoint Inhibitor Failures Is an Unmet Need in Non-Small Cell Lung Cancer Patient Population NANTES, France, July 02, [...]

ESPERITE N.V. (ESP) SELLS ITS STAKE IN CRYOSAVE SOUTH AFRICA TO GO LIFE HEALTHCARE (GLI).

02/07/2018 - 07:18

CryoSave in its joint venture with Ecsponent (ECS) at equal participation have sold 100% of their stake for ZAR 50,000,000 (Fifty Million South African Rand). As a leading stem cells bank, CryoSave SA will continue to [...]

Adamis Pharmaceuticals Announces Distribution and Commercialization Agreement for Symjepi

02/07/2018 - 02:00

SAN DIEGO, July 01, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced today that it has entered into an exclusive distribution and commercialization agreement with Sandoz Inc [...]

Align Technology Provides Update Regarding SmileDirectClub (SDC) Dispute

30/06/2018 - 01:10

Judge Denies SDC’s Request for Temporary Injunction SAN JOSE, Calif., June 29, 2018 (GLOBE NEWSWIRE) -- Align Technology, Inc. (Nasdaq:ALGN) today provided an update to its April 25, 2018 disclosure regarding SDC [...]

MedMira Reports Third Quarter Results

30/06/2018 - 01:00

HALIFAX, Nova Scotia, June 29, 2018 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the quarter ended April 30, 2018. Q3 FY2018 Financial Results Highlights Profit and [...]